IRIS
Armenia, Daniele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.165
NA - Nord America 933
SA - Sud America 358
EU - Europa 342
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.848
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 850
SG - Singapore 376
BR - Brasile 290
IT - Italia 250
CN - Cina 233
HK - Hong Kong 160
BD - Bangladesh 139
VN - Vietnam 82
MX - Messico 42
IN - India 32
AR - Argentina 28
GB - Regno Unito 25
CA - Canada 21
TR - Turchia 21
ID - Indonesia 20
IQ - Iraq 17
ZA - Sudafrica 15
PK - Pakistan 14
RU - Federazione Russa 14
FR - Francia 12
EC - Ecuador 11
PH - Filippine 9
SA - Arabia Saudita 9
UA - Ucraina 9
UZ - Uzbekistan 9
VE - Venezuela 8
MY - Malesia 7
TN - Tunisia 7
CO - Colombia 6
DE - Germania 6
MA - Marocco 6
NP - Nepal 6
PL - Polonia 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
CL - Cile 4
GT - Guatemala 4
JM - Giamaica 4
KE - Kenya 4
AZ - Azerbaigian 3
CM - Camerun 3
EG - Egitto 3
HN - Honduras 3
JO - Giordania 3
LB - Libano 3
NL - Olanda 3
OM - Oman 3
PE - Perù 3
SN - Senegal 3
BB - Barbados 2
BE - Belgio 2
BO - Bolivia 2
KR - Corea 2
NI - Nicaragua 2
PR - Porto Rico 2
PT - Portogallo 2
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CU - Cuba 1
DZ - Algeria 1
ES - Italia 1
ET - Etiopia 1
FI - Finlandia 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
HT - Haiti 1
HU - Ungheria 1
JP - Giappone 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MN - Mongolia 1
MZ - Mozambico 1
NA - Namibia 1
PS - Palestinian Territory 1
RE - Reunion 1
RO - Romania 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 2.848
Salva come PNG Salva come JPEG
Città #
San Jose 388
Singapore 199
Rome 194
Hong Kong 156
Ashburn 128
Beijing 115
Santa Clara 67
Ho Chi Minh City 36
Mexico City 32
Hanoi 21
São Paulo 19
Rio de Janeiro 17
Los Angeles 13
Buffalo 12
New York 12
Dallas 11
Belo Horizonte 9
Dhaka 9
Baltimore 8
Oxford 8
Tashkent 8
Bicester 7
Milan 7
Secaucus 7
Baghdad 6
Brasília 6
Curitiba 6
Istanbul 6
Miami 6
Ipatinga 5
Joinville 5
Quito 5
Bari 4
Da Nang 4
Erbil 4
Goiânia 4
Kingston 4
Philadelphia 4
Salvador 4
São Gonçalo 4
Toronto 4
Tunis 4
Abu Dhabi 3
Amman 3
Asunción 3
Atlanta 3
Bagé 3
Bauru 3
Beirut 3
Brooklyn 3
Cachoeiro de Itapemirim 3
Campinas 3
Cape Town 3
Chicago 3
Guarulhos 3
Haiphong 3
Hyderabad 3
Jakarta 3
Johannesburg 3
João Pessoa 3
Juiz de Fora 3
Kaifeng 3
Karachi 3
Kathmandu 3
Kuala Lumpur 3
Lahore 3
Ludhiana 3
Montreal 3
Muscat 3
Novosibirsk 3
Porto Alegre 3
Pretoria 3
Santiago 3
Volta Redonda 3
Antakya 2
Bacoor 2
Bekasi 2
Boa Vista 2
Bogotá 2
Bridgetown 2
Buenos Aires 2
Cabo Frio 2
Cajamar 2
Cambé 2
Can Tho 2
Caracas 2
Casablanca 2
Castanhal 2
Catania 2
Caxias do Sul 2
Chandigarh 2
Columbus 2
Dakar 2
Dammam 2
Delhi 2
Diamantina 2
Durban 2
Faisalabad 2
Fort Worth 2
Fortaleza 2
Totale 1.716
Salva come PNG Salva come JPEG
Nome #
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 85
Confirmed virological failure following enhanced adherence counseling among virally unsuppressed children and adolescents on dolutegravir-based versus other regimens: Evidence from a cohort analysis in Cameroon 83
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 68
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 68
HIV MDR is still a relevant issue despite its dramatic drop over the years 66
Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice 64
Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing 64
Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals 57
A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naive Patients Starting a First-Line HAART 57
Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study 54
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings 52
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 51
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 51
Impact of baseline HIV-1 integrase polymorphisms on virological outcome in a large European cohort of patients starting a raltegravir-containing regimen 51
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study 50
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 43
PRESTIGIO RING: "A 28-year-old highly treatmentexperienced man with vertical HIV infection on ibalizumab therapy: ART simplification perspectives" 42
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients 42
Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells 41
Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries 40
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 39
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases 38
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 38
A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection 38
Anti-HIV-1 activity of new integrase inhibitors in lymphocytes and human primary macrophages 37
Hepatitis B Surface Antigen Genetic Elements Critical for Immune Escape Correlate With Hepatitis B Virus Reactivation Upon Immunosuppression 37
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries 37
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 37
HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression 37
Emerging patterns and implications of HIV-1 integrase inhibitor resistance 36
BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS 36
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B 36
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma 36
Darunavir (DRV)/r plus raltegravir (RAL) dual regimen in multi-experienced population: long term efficacy and tolerability 36
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings 36
Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors 35
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 35
Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens 35
Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance? 34
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBVcoinfected patients on first-line therapy 34
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 34
Impact of pre-therapy viral load on virological response to modern first-line HAART 34
A high HBsAg genetic complexity can influence HBV immunogenicity in the setting of acute infection 33
Virological response and resistance in multi-experienced patients treated with raltegravir 33
The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing 33
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 32
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors 32
Selection and coevolution of mutational patterns in the HIV-1 integrase characterized by pyrosequencing analysis 32
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 32
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 32
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype 31
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy 31
Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors 31
P696 A COMPLEX HBV QUASISPECIES IN RT AND HBsAg CHARACTERIZES PATIENTS WITH ACUTE HEPATITIS B: A REFINED UDPS ANALYSIS 30
Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers 30
HIV-1 INTEGRASE MUTATIONS, FOUND AS MINORITY QUASISPECIES IN PATIENTS NAIVE TO INTEGRASE INHIBITORS, ARE ASSOCIATED WITH DECREASED SUSCEPTIBILITY TO RALTEGRAVIR AND ELVITEGRAVIR IN VITRO 30
Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage 30
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. 30
Secondary Integrase Resistance Mutations Found in HIV-1 Minority Quasispecies in Integrase Therapy-Naive Patients Have Little or No Effect on Susceptibility to Integrase Inhibitors 29
Natural raltegravir-resistance is a rare event in integrase-inhibitors naive patients, and when present, is confined to a restricted minority of secondary variants and is not associated with virological response to raltegravir 29
P681 HBsAg MUTATIONS WITH ENHANCED CAPABILITY TO EVADE IMMUNE RESPONSE ARE ASSOCIATED WITH HBV REACTIVATION DURING IMMUNOSUPPRESSION 29
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. 29
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 28
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 28
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 28
P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing 28
IMPACT OF MUTATIONS AT POSITION 135 OF HIV-1 REVERSE TRANSCRIPTASE ON VIROLOGIC RESPONSE TO A FIRST LINE NNRTI-CONTAINING HAART 27
Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. 27
Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation 25
Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels 25
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients 25
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 25
THE LOWEST X4 GENO2PHENO-FALSE POSITIVE RATE IS ASSOCIATED WITH GREATER CD4-DEPLETION 24
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. 23
P0580 : Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome 22
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors 20
Totale 2.897
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.843
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.843
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20242 0 0 0 0 0 0 0 0 0 0 0 2
2024/2025826 55 0 12 104 17 11 101 97 45 28 176 180
2025/20262.069 118 10 151 127 194 156 196 80 416 240 192 189
Totale 2.897